Tenalisib (RP6530, selective dual PI3K d/γ inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial in patients with locally advanced or metastatic HR+/HER2- breast cancer (mBC)
RP12146, Rhizen’s next generation PARP1/2 inhibitor concludes dose escalation phase with a favorable safety pro has moved to the dose expansion phase in solid tumors
BASEL, Switzerland--(BUSINESS WIRE)-- Rhizen Pharmaceuticals AG (Rhizen), a Swiss based privately held, clinical-stage biopharmaceutical company announced today that it is presenting data from an ongoing Phase 2 trial of Tenalisib in locally advanced or metastatic breast cancer and data from a concluded dose escalation phase of RP12146 at ESMO 2022, Paris from Sept 9-13, 2022.
The multi-centre, randomized phase II study evaluating two doses of Tenalisib, a differentiated PI3K δ/γ inhibitor with additional SIK3 inhibitory activity, has completed 24 weeks of treatment with an impressive Clinical Benefit Rate (CBR) of 57.5% and with no unexpected safety concerns. Treatment with orally dosed Tenalisib was found to be effective in a difficult to treat population where majority of patients had visceral disease and multiple metastatic lesions. In addition, a lone TNBC patient in the trial showed stable disease for more than 6 months and is continuing on the study.
Dose escalation of a Phase -I/Ib trial of RP12146, a next generation PARP 1/2 inhibitor designed to overcome the safety liabilities associated with first generation PARP inhibitors, was successfully completed and is enrolling at the RP2D dose for the expansion phase. RP12146 showed dose related exposures with robust target engagement and notable absence of haematological toxicities viz anaemia and cytopenia. The expansion phase at 400mg BID is currently in progress in genomically qualified ovarian, breast and prostate cancer patients with HRR mutations.
“We are pleased to report the clinical progress of our assets, particularly Tenalisib in a difficult to treat patient population of metastatic breast cancer showing sustained and beneficial disease control. In addition, our carefully designed next generation PARP1/2 inhibitor has successfully demonstrated the safety differential to first generation agents of this class and we are planning to rapidly progress into efficacy evaluations in various solid tumors as mono therapy and as rational combinations,” said Swaroop Vakkalanka, Founder & CEO of Rhizen Pharmaceuticals AG.
Tenalisib Poster Presentation schedule:
224P - Efficacy and safety of Tenalisib, a PI3K delta/gamma and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Results from a phase II study
Presentation Number: 224P
Speakers: Tamta Makharadze (Tbilisi, Georgia)
Poster Session: Breast cancer, metastatic
Date: Sat, 10.09.2022
Hall 4: Presentation time: (12:00-13:00 CEST)
RP12146 Poster Presentation schedule:
483P - Pre-clinical and early clinical assessment of the safety and anti-tumor activity of RP12146, a PARP1/2 inhibitor in solid tumors
Presentation Number: 483P
Speakers: Piotr Tomczak (Poznan, Poland)
Poster Session: Developmental therapeutics
Date: Mon, 12.09.2022
Hall 4: Presentation time: (12:00-13:00 CEST)
About Rhizen Pharmaceuticals AG:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.
Rhizen is headquartered in Basel, Switzerland. For additional information, please visit
Forward-looking statements
This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
View source version on businesswire.com:
Contacts
Rhizen Pharmaceuticals AG - Contact:
Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals AG.
Telephone: +41 32 580 0113
Email: corpcomm@rhizen.com
Source: Rhizen Pharmaceuticals AG
View this news release online at:
